Activist short-seller Spruce Point Capital Management is taking aim at medical device company Stryker (SYK). Spruce Point unveiled its latest attack on Wednesday, saying Stryker has overpaid for recent acquisitions, has used questionable accounting practices and has executive compensation that isn’t aligned with shareholder interests. The activist has called on Harvard Business School dean and Stryker audit committee member Srikant Datar to evaluate its findings with “independent forensic… Source link
Read More »DWAC dips 10% after short-seller Iceberg bets against stock
Shares of Digital World Acquisition Corp (DWAC), the special purpose acquisition which plans to take former President Donald Trump’s social media venture public slid 10% on Monday afternoon after short-seller Iceberg Research announced it was betting against the stock. “We are short $DWAC,” wrote Iceberg Research in a tweet. DWAC shares had jumped more than 800% over the span of two sessions last week after Digital World Acquisition announced it was taking Trump Media and Technology Group… Source link
Read More »‘We really are not even in the beginning stages’ of the tech crackdown, short-seller says
Beijing’s latest moves to crackdown on various sectors in the Chinese economy is spooking some investors, and one short seller believes that this is simply the start. “I know the bulls wanted to say: ‘It’s just going to be the education stocks,’ and then it was the crackdown on gaming,” short seller Dan David told Yahoo Finance Live (video above). In the last few months, the Chinese government under President Xi Jinping has started tightening regulations across various sectors such as… Source link
Read More »Flying taxi maker EHang shares rebound 40% after response to short-seller
TipRanks The Bottom Is in for These 2 Stocks? Analysts Say ‘Buy’ Today, we’re looking at two small-cap biotech firms whose stocks have struck a rut. Each company has hit a recent clinical setback that sent the share price falling, erasing previous gains and sending it back down to low levels. Setbacks of this sort are not uncommon in the biotech industry, and in fact highlight the risk and speculative nature of the industry. So what should investors do, when a stock collapses? Is this a… Source link
Read More »